Breast cancer groups bearing germline and somatic BRCA2 mutations as well as non-mutated patients were characterized by the upregulation of luminal subtype signatures such as ESR1, TFF1, TFF2 [27]. This evidence concerns the gene BRCA2 and breast carcinoma.